Innate immune processes in lupus erythematosus

被引:27
作者
Aringer, Martin [1 ]
Guenther, Claudia [2 ]
Lee-Kirsch, Min Ae [3 ]
机构
[1] Tech Univ Dresden, Div Rheumatol, Dept Med 3, Univ Clin Ctr Carl Gustav Carus, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Dept Dermatol, Univ Clin Ctr Carl Gustav Carus, D-01307 Dresden, Germany
[3] Tech Univ Dresden, Div Mol Genet, Dept Pediat, Univ Clin Ctr Carl Gustav Carus, D-01307 Dresden, Germany
关键词
Lupus; Cytokines; TREX1; RNase-H2; SAMHD1; AICARDI-GOUTIERES-SYNDROME; FAMILIAL CHILBLAIN LUPUS; TUMOR-NECROSIS-FACTOR; PLASMACYTOID DENDRITIC CELLS; INTERFERON REGULATORY FACTOR; RESTRICTION FACTOR SAMHD1; TOLL-LIKE RECEPTORS; AUTOIMMUNE-DISEASE; EXONUCLEASE TREX1; RHEUMATOID-ARTHRITIS;
D O I
10.1016/j.clim.2012.11.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The innate immune system is involved in the pathogenesis of systemic autoimmune diseases such as systemic lupus erythematosus (SLE) or dermatomyositis. The important role of complement factors of the classical pathway and of Toll like receptors (TLRs) is well established, based on genetic and clinical evidence. Immune complexes activate tumor necrosis factor (THE) in myeloid cells and interferon-alpha (IFN alpha) in plasmacytoid dendritic cells. The latter initiates a positive feedback loop that drives autoimmunity. More recently, mutations in genes encoding intracellular enzymes involved in RNA and DNA handling, which likewise lead to increased IFNa, have been found to cause familial chilblain lupus and to be associated with SLE. Within the immunological disease continuum, these disorders can be placed between autoinflammation and autoimmunity, and we would propose the term autoadjuvant for this group, since the activation of the innate immune system in these diseases appears to lower the threshold for (auto)immune reactions. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:216 / 222
页数:7
相关论文
共 86 条
[11]  
2-K
[12]   Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies [J].
Bengtsson, AA ;
Sturfelt, G ;
Truedsson, L ;
Blomberg, J ;
Alm, G ;
Vallin, H ;
Rönnblom, L .
LUPUS, 2000, 9 (09) :664-671
[13]   Interferon and granulopoiesis signatures in systemic lupus erythematosus blood [J].
Bennett, L ;
Palucka, AK ;
Arce, E ;
Cantrell, V ;
Borvak, J ;
Banchereau, J ;
Pascual, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :711-723
[14]   EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics [J].
Bertsias, G. ;
Ioannidis, J. P. A. ;
Boletis, J. ;
Bombardieri, S. ;
Cervera, R. ;
Dostal, C. ;
Font, J. ;
Gilboe, I. M. ;
Houssiau, F. ;
Huizinga, T. ;
Isenberg, D. ;
Kallenberg, C. G. M. ;
Khamashta, M. ;
Piette, J. C. ;
Schneider, M. ;
Smolen, J. ;
Sturfelt, G. ;
Tincani, A. ;
van Vollenhoven, R. ;
Gordon, C. ;
Boumpas, D. T. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :195-205
[15]   Syndromes and complications of interferon therapy [J].
Borg, Frances A. Y. ;
Isenberg, David A. .
CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (01) :61-66
[16]   Complement in human diseases: Lessons from complement deficiencies [J].
Botto, Marina ;
Kirschfink, Michael ;
Macor, Paolo ;
Pickering, Matthew C. ;
Wuerzner, Reinhard ;
Tedesco, Francesco .
MOLECULAR IMMUNOLOGY, 2009, 46 (14) :2774-2783
[17]   The lupus paradox [J].
Carroll, MC .
NATURE GENETICS, 1998, 19 (01) :3-4
[18]   AUTOANTIGENS TARGETED IN SYSTEMIC LUPUS-ERYTHEMATOSUS ARE CLUSTERED IN 2 POPULATIONS OF SURFACE-STRUCTURES ON APOPTOTIC KERATINOCYTES [J].
CASCIOLAROSEN, LA ;
ANHALT, G ;
ROSEN, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (04) :1317-1330
[19]   Immune Complex-Mediated Cell Activation from Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients Elaborate Different Requirements for IRAK1/4 Kinase Activity across Human Cell Types [J].
Chiang, Eugene Y. ;
Yu, Xin ;
Grogan, Jane L. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (02) :1279-1288
[20]   Type I interferon in organ-targeted autoimmune and inflammatory diseases. [J].
Crow M.K. .
Arthritis Research & Therapy, 12 (Suppl 1) :S5